Denali Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
DNLI$19.85-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 144,220,986 | $1,768 | $2,764,880 | $2,020 | $(1,538,984) | $1,229,684 |
| Issuances under equity incentive plans | 1,042,249 | 11 | 5,224 | — | — | 5,235 |
| Vesting of restricted stock units | 1,362,487 | 14 | (14) | — | — | — |
| Stock-based compensation | — | — | 76,188 | — | — | 76,188 |
| Net loss | — | — | — | — | (383,991) | (383,991) |
| Other comprehensive loss | — | — | — | (919) | — | (919) |
| Balance at September 30, 2025 | 146,625,722 | $1,793 | $2,846,278 | $1,101 | $(1,922,975) | $926,197 |
| Balance at June 30, 2025 | 145,685,442 | $1,783 | $2,820,404 | $939 | $(1,796,073) | $1,027,053 |
| Issuances under equity incentive plans | 586,914 | 6 | 577 | — | — | 583 |
| Vesting of restricted stock units | 353,366 | 4 | (4) | — | — | — |
| Stock-based compensation | — | — | 25,301 | — | — | 25,301 |
| Net loss | — | — | — | — | (126,902) | (126,902) |
| Other comprehensive income | — | — | — | 162 | — | 162 |
| Balance at September 30, 2025 | 146,625,722 | $1,793 | $2,846,278 | $1,101 | $(1,922,975) | $926,197 |
| Balance at December 31, 2023 | 138,385,498 | $1,711 | $2,144,811 | $643 | $(1,116,211) | $1,030,954 |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $480 | 3,244,689 | 32 | 499,221 | — | — | 499,253 |
| Issuances under equity incentive plans | 948,705 | 10 | 13,224 | — | — | 13,234 |
| Vesting of restricted stock units | 1,261,137 | 11 | (11) | — | — | — |
| Stock-based compensation | — | — | 78,188 | — | — | 78,188 |
| Net loss | — | — | — | — | (308,020) | (308,020) |
| Other comprehensive income | — | — | — | 4,886 | — | 4,886 |
| Balance at September 30, 2024 | 143,840,029 | $1,764 | $2,735,433 | $5,529 | $(1,424,231) | $1,318,495 |
| Balance at June 30, 2024 | 143,123,582 | $1,757 | $2,704,992 | $(2,659) | $(1,317,039) | $1,387,051 |
| Issuances under equity incentive plans | 291,183 | 3 | 5,453 | — | — | 5,456 |
| Vesting of restricted stock units | 425,264 | 4 | (4) | — | — | — |
| Stock-based compensation | — | — | 24,992 | — | — | 24,992 |
| Net loss | — | — | — | — | (107,192) | (107,192) |
| Other comprehensive income | — | — | — | 8,188 | — | 8,188 |
| Balance at September 30, 2024 | 143,840,029 | $1,764 | $2,735,433 | $5,529 | $(1,424,231) | $1,318,495 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.